AIM Advances
AIM ImmunoTech accelerates toward a potential pivotal pancreatic cancer program as Ampligen advances through key clinical milestones
AIM - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesRecent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity